Agreement signedPublished 10 Oct 2023

Haemonetics Corporation /
OpSens, Inc.

Haemonetics to acquire OpSens in an all-cash deal

Buy side: Haemonetics Corporation
Buy sideHaemonetics Corporation
Target: OpSens, Inc.
TargetOpSens, Inc.
Source · 10 Oct 2023
Buy side: Haemonetics Corporation
Buy sideHaemonetics Corporation
Target: OpSens, Inc.
TargetOpSens, Inc.
01 / BuyerHaemonetics Corporation
02 / TargetOpSens, Inc.
01

What happened

Haemonetics Corporation agreed to acquire all outstanding shares of OpSens, Inc. for CAD $2.90 per share in cash. The transaction represents a fully diluted equity value of approximately USD $253 million.

OpSens offers optical technology primarily for use in interventional cardiology. Closing is subject to shareholder, court and regulatory approvals and other customary conditions.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Haemonetics to acquire OpSens in an all-cash deal

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.